DP Biology Questionbank

Description

Nature of science:
Developments in scientific research follow improvements in technology—innovation in technology has allowed scientists to diagnose and treat diseases. (1.8)Understandings:

• Infection by a pathogen can be detected by the presence of its genetic material or by its antigens.
• Predisposition to a genetic disease can be detected through the presence of markers.
• DNA microarrays can be used to test for genetic predisposition or to diagnose the disease.
• Metabolites that indicate disease can be detected in blood and urine.
• Tracking experiments are used to gain information about the localization and interaction of a desired protein.
• Biopharming uses genetically modified animals and plants to produce proteins for therapeutic use.
• Viral vectors can be used in gene therapy.

Applications and skills:

• Application: Use of PCR to detect different strains of influenza virus.
• Application: Tracking tumour cells using transferin linked to luminescent probes.
• Application: Biopharming of antithrombin.
• Application: Use of viral vectors in the treatment of Severe Combined Immunodeficiency (SCID).
• Skill: Analysis of a simple microarray.
• Skill: Interpretation of the results of an ELISA diagnostic test.

Theory of knowledge:

• There have been cases around the world where subjects have died as a consequence of participating in a gene therapy research protocol. How is the decision to proceed with risky procedures made?
• What constitutes an acceptable level of risk for allowing humans to be involved in scientific research?

Utilization:
Syllabus and cross-curricular links:
Biology
Topic 3.5 Genetic modification and biotechnology
Topic 6.3 Defence against infectious disease
Topic 11.1 Antibody production and vaccination

Directly related questions

• 17N.3.HL.TZ0.13: Discuss biopharming.
• 17N.3.HL.TZ0.10d: Outline possible medical applications of the polymerase chain reaction (PCR).
• 17M.3.HL.TZ2.12b: Outline the use of luminescent probes in the treatment of tumours.
• 17M.3.HL.TZ2.12a: Outline one way in which genetic sequences can be used to indicate predisposition to a disease.
• 17M.3.HL.TZ1.11c: Outline the use of microarrays to test for genetic disease.
• 17M.3.HL.TZ1.11b: Evaluate the use of viral vectors in gene therapy.
• 17M.3.HL.TZ1.11a.ii: Outline two uses of genetic markers.
• 17M.3.HL.TZ1.11a.i: Outline what is meant by the term genetic markers.
• 17M.3.SL.TZ1.16a: Calculate the diversity of site C. Working should be shown.
• 17M.2.HL.TZ1.1f.ii: Suggest a reason for the greater expression of the gene for the urea transporter after an...
• 16N.3.HL.TZ0.11b: Discuss the implications of biopharming using a specific example.
• 16N.3.HL.TZ0.11a: Metabolites that indicate disease can be detected in urine. State a metabolite found in urine and...
• 16M.3.HL.TZ0.13: Explain how infection by a pathogen can be detected by an ELISA test for antigens.
• 15M.3.SL.TZ2.17a: Outline how a defective gene can be replaced using viral vectors.
• 15M.3.HL.TZ1.7a: Identify the age and ethnic group of the individual with the highest diversity of gut bacterial...
• 15M.3.HL.TZ1.7b (i): Outline the trends in the number of bacterial species in the digestive tracts of Amerindians.
• 15M.3.HL.TZ1.7b (ii): Distinguish between the trends seen in the three populations.
• 15M.3.HL.TZ1.7c: Suggest two reasons for how the different environments of the three human populations affect the...
• 15M.3.HL.TZ1.7d: A century ago, it was discovered that each person belonged to one of four blood types.  Now some...
• 15M.3.SL.TZ1.18c: Identify one risk associated with gene therapy.
• 15M.3.HL.TZ2.8a: Outline how a defective gene can be replaced using viral vectors.
• 15N.3.SL.TZ0.16a: State the percentage of P. aeruginosa that were resistant to fluoroquinolone in 1996.
• 15N.3.SL.TZ0.16b: Compare the trends in fluoroquinolone use and resistance to fluoroquinolone in other...
• 15N.3.SL.TZ0.16c: Predict the results if data from the same hospitals were collected for P. aeruginosa resistance...
• 15N.3.SL.TZ0.16d: Discuss the implications of the data in the graph for the health of patients.
• 15N.3.SL.TZ0.18b: Researchers are studying several ways to treat cancer using gene therapy. Discuss the risks of...
• 13M.3.SL.TZ2.17c: Discuss the possible consequences of gene therapy.
• 11M.3.SL.TZ1.18c: Discuss the risks of gene therapy.
• 11M.3.SL.TZ2.17a: Describe the use of viral vectors in gene therapy.
• 12M.3.SL.TZ1.18a: Gene therapy is a new technology which can be used to treat hereditary diseases. Outline two...
• 10M.3.HL.TZ1.9: Discuss methods used in gene therapy, including the risks involved.
• 10M.3.SL.TZ2.18b: Discuss risks of gene therapy.
• 10M.3.SL.TZ2.18a: Gene therapy may offer cures for inherited diseases and, perhaps, improve quality of life....
• 11N.3.HL.TZ0.9: Discuss the use of viral vectors in gene therapy including the risks involved.
• 11N.3.SL.TZ0.17b: Outline the use of viral vectors in gene therapy.
• 09N.3.HL.TZ0.9: Discuss the risks of gene therapy including safety, conflict of interest and ethical arguments.
• 09N.3.SL.TZ0.17b: Outline the use of viral vectors in gene therapy.